Candido Marina Ferreira, Medeiros Mariana, Veronez Luciana Chain, Bastos David, Oliveira Karla Laissa, Pezuk Julia Alejandra, Valera Elvis Terci, Brassesco María Sol
Department of Cell Biology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14049-900, SP, Brazil.
Regional Blood Center, University of São Paulo, Ribeirão Preto 14049-900, SP, Brazil.
Pharmaceutics. 2023 Feb 16;15(2):664. doi: 10.3390/pharmaceutics15020664.
Childhood cancer is considered rare, corresponding to ~3% of all malignant neoplasms in the human population. The World Health Organization (WHO) reports a universal occurrence of more than 15 cases per 100,000 inhabitants around the globe, and despite improvements in diagnosis, treatment and supportive care, one child dies of cancer every 3 min. Consequently, more efficient, selective and affordable therapeutics are still needed in order to improve outcomes and avoid long-term sequelae. Alterations in kinases' functionality is a trademark of cancer and the concept of exploiting them as drug targets has burgeoned in academia and in the pharmaceutical industry of the 21st century. Consequently, an increasing plethora of inhibitors has emerged. In the present study, the expression patterns of a selected group of kinases (including tyrosine receptors, members of the PI3K/AKT/mTOR and MAPK pathways, coordinators of cell cycle progression, and chromosome segregation) and their correlation with clinical outcomes in pediatric solid tumors were accessed through the R2: Genomics Analysis and Visualization Platform and by a thorough search of published literature. To further illustrate the importance of kinase dysregulation in the pathophysiology of pediatric cancer, we analyzed the vulnerability of different cancer cell lines against their inhibition through the Cancer Dependency Map portal, and performed a search for kinase-targeted compounds with approval and clinical applicability through the CanSAR knowledgebase. Finally, we provide a detailed literature review of a considerable set of small molecules that mitigate kinase activity under experimental testing and clinical trials for the treatment of pediatric tumors, while discuss critical challenges that must be overcome before translation into clinical options, including the absence of compounds designed specifically for childhood tumors which often show differential mutational burdens, intrinsic and acquired resistance, lack of selectivity and adverse effects on a growing organism.
儿童癌症被认为是罕见病,约占人类所有恶性肿瘤的3%。世界卫生组织(WHO)报告称,全球每10万居民中普遍有超过15例病例,尽管在诊断、治疗和支持性护理方面有所改善,但每3分钟仍有一名儿童死于癌症。因此,仍需要更高效、更具选择性且更经济实惠的治疗方法,以改善治疗效果并避免长期后遗症。激酶功能的改变是癌症的一个特征,将其作为药物靶点的概念在21世纪的学术界和制药行业中迅速发展。因此,出现了越来越多的抑制剂。在本研究中,通过R2:基因组学分析和可视化平台以及全面检索已发表的文献,研究了一组选定的激酶(包括酪氨酸受体、PI3K/AKT/mTOR和MAPK途径的成员、细胞周期进程协调因子以及染色体分离相关激酶)的表达模式及其与小儿实体瘤临床结果的相关性。为了进一步说明激酶失调在小儿癌症病理生理学中的重要性,我们通过癌症依赖性图谱门户分析了不同癌细胞系对其抑制的敏感性,并通过CanSAR知识库搜索了已获批且具有临床适用性的激酶靶向化合物。最后,我们对大量在实验测试和临床试验中用于治疗小儿肿瘤的、可减轻激酶活性的小分子进行了详细的文献综述,同时讨论了在转化为临床治疗方案之前必须克服的关键挑战,包括缺乏专门为儿童肿瘤设计的化合物,儿童肿瘤往往表现出不同的突变负担、内在和获得性耐药性、缺乏选择性以及对生长中的生物体产生不良反应。